Corcept Therapeutics Incorporated (CORT)
Company Info
Highlights
$7.72B
$1.23
59.16
0.61
$685.45M
$674.70M
$111.33M
$25.35 - $117.33
$143.25
16.31%
5.44
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Corcept Therapeutics Incorporated, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Corcept Therapeutics Incorporated (CORT) returned 39.83% year-to-date (YTD) and 187.83% over the past 12 months. Over the past 10 years, CORT delivered an annualized return of 29.13%, outperforming the S&P 500 benchmark at 10.31%.
CORT
39.83%
-5.61%
29.93%
187.83%
39.49%
29.13%
^GSPC (Benchmark)
-4.26%
11.24%
-5.02%
8.55%
14.02%
10.31%
Monthly Returns
The table below presents the monthly returns of CORT, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 32.80% | -9.47% | 88.54% | -37.07% | -1.98% | 39.83% | |||||||
| 2024 | -35.04% | 11.37% | 7.19% | -7.42% | 29.37% | 7.69% | 19.02% | -8.71% | 31.10% | 5.81% | 17.79% | -12.64% | 55.14% |
| 2023 | 12.56% | -8.88% | 3.98% | 4.02% | 4.26% | -5.28% | 14.52% | 28.45% | -16.76% | 3.06% | -9.29% | 27.52% | 59.92% |
| 2022 | -5.20% | 18.75% | 1.03% | -4.48% | -3.11% | 14.11% | 20.52% | -9.91% | -0.70% | 11.54% | -11.61% | -19.66% | 2.58% |
| 2021 | 8.03% | -11.00% | -5.41% | -4.20% | -5.22% | 1.85% | -5.59% | 2.46% | -7.52% | -8.54% | 16.67% | -5.71% | -24.31% |
| 2020 | 4.71% | -0.39% | -5.78% | 6.48% | 19.59% | 11.10% | -11.12% | -15.05% | 37.05% | -3.59% | 34.92% | 15.55% | 116.20% |
| 2019 | -16.32% | 11.54% | -5.85% | 5.45% | -21.00% | 14.01% | 0.99% | 11.99% | 12.09% | 3.22% | -12.06% | -5.69% | -9.43% |
| 2018 | 27.44% | -34.00% | 8.29% | 1.40% | 10.91% | -15.03% | -16.48% | 14.39% | -6.66% | -16.19% | 18.55% | -4.09% | -26.02% |
| 2017 | -2.07% | 26.44% | 21.91% | -12.96% | 18.55% | 4.33% | 5.68% | 33.68% | 15.78% | 2.02% | -8.89% | 0.67% | 148.76% |
| 2016 | -26.71% | 4.66% | 22.51% | 1.92% | 24.74% | -8.24% | 6.23% | -8.10% | 21.95% | 6.77% | 20.89% | -13.47% | 45.78% |
| 2015 | -3.00% | 13.75% | 69.18% | 3.04% | 6.07% | -1.80% | -16.14% | -0.79% | -24.80% | -1.86% | 43.09% | -5.68% | 66.00% |
| 2014 | 7.17% | -4.65% | 32.93% | 1.38% | -48.87% | 23.89% | -14.64% | 15.48% | -2.90% | 21.27% | -6.77% | -0.99% | -6.54% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 96, CORT is among the top 4% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Corcept Therapeutics Incorporated (CORT) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Corcept Therapeutics Incorporated. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Corcept Therapeutics Incorporated was 94.28%, occurring on Oct 13, 2006. Recovery took 2670 trading sessions.
The current Corcept Therapeutics Incorporated drawdown is 38.31%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -94.28% | Apr 15, 2004 | 630 | Oct 13, 2006 | 2670 | May 26, 2017 | 3300 |
| -61.65% | Jan 30, 2018 | 336 | May 31, 2019 | 389 | Dec 14, 2020 | 725 |
| -45.91% | Feb 9, 2021 | 245 | Jan 27, 2022 | 380 | Aug 3, 2023 | 625 |
| -45.51% | Apr 1, 2025 | 13 | Apr 17, 2025 | — | — | — |
| -37.57% | Sep 15, 2023 | 95 | Jan 31, 2024 | 87 | Jun 5, 2024 | 182 |
Volatility
Volatility Chart
The current Corcept Therapeutics Incorporated volatility is 17.50%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Corcept Therapeutics Incorporated over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Corcept Therapeutics Incorporated, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -38.6%.
Valuation
The Valuation section provides an overview of how Corcept Therapeutics Incorporated is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for CORT, comparing it with other companies in the Biotechnology industry. Currently, CORT has a P/E ratio of 59.2. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for CORT compared to other companies in the Biotechnology industry. CORT currently has a PEG ratio of 0.6. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CORT relative to other companies in the Biotechnology industry. Currently, CORT has a P/S ratio of 11.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CORT in comparison with other companies in the Biotechnology industry. Currently, CORT has a P/B value of 11.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |